Efficacy of sunitinib in patients with renal cell carcinoma with bone metastases

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 5165-5168

  Paule, Bernard ^a   Brion, Nathalie ^b,c  

^a HENRI MONDOR HOSPITAL   (France)

^b CENTRE HOSPITALIER DE VERSAILLES   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Bone metastases; Renal cell carcinoma; Sunitinib malate; Tyrosine kinase inhibitor

Indexed keywords

SUNITINIB;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE METASTASIS; BONE SCINTISCANNING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LAMINECTOMY; LOW BACK PAIN; MALE; NEPHRECTOMY; PRIORITY JOURNAL; SACRUM; TREATMENT OUTCOME;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MIDDLE AGED; PYRROLES;

EID: 78751557271     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Martel CL and Lara PN: Renal cell carcinoma: current Status and future directions. Crit Rev Oncol Hematol 45: 177-190, 2003.
2. Janzen NK, Kim HL, Figlin RA and Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North 30: 843-852, 2003.
3. Coleman RE: Skeletal complications of malignancy. Cancer 80: 1588-1594, 1997.
4. Costa L and Major PP: Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6: 163-174, 2009.
5. Vogl UM, Zehetgruber H, Dominkus M Hejna M, Zielinski CC, Haitel A and Schmidinger M: Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer 95: 691-698, 2006.
6. Abrams TJ, Lee LB, Murray LJ, Pryer N and Cherrington JM: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471-478, 2003.
7. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, Lee SJ, Jo K and Shong M: An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91: 4070-4076, 2006.
8. Mendel DB, Laird AD, Xin X Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon and Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327-337, 2003.
9. O'Farrell AM, Abrams TJ, Yuen HA Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich M and Cherrington JM; SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101: 3597-3605, 2003.
10. Motzer RJ, Hutson TE, Tomczak P Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang and Figlin RA: Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590, 2009.
11. Ljungberg B, Cowan N, Hanbury DC Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF and Sinescu IC; European Association of Urology Guideline Group. Guidelines on renal cell carcinoma (2010). European Association of Urology http://www.uroweb.org/?id=218&gid=4.
12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer v.2.2010. http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp
13. Roodman GD. Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer 97: 73-738, 2003.
14. Xu L, Tong R, Cochran DM and Jain RK: Blocking plateletderived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 65: 571-5719, 2005.
15. Zhang Z, Chen J and Jin D: Platelet-derived growth factor (PDGF)-BB stimulates osteoclastic bone resorption directly: the role of receptor beta. Biochem Biophys Res Commun 251: 19194, 1998.
16. Paule B, Clerc D, Rudant C Coulombel C, Bonhomme-Faivre L, Quillard J and Bisson M: Enhanced expression of interleukin-6 in bone and serum of metastatic renal cell carcinoma. Hum Pathol 29: 42-424, 1998.
17. Paule B, Deslandes E, Le Mouel SE Bastien L, Podgorniak MP, Allory Y, de la Taille A, Menashi S, Calvo F and Mourah S: Identification of a novel biomarker signature associated with risks for bone metastasis in patients with renal cell carcinoma. Int J Biol Markers 25: 112-5, 2010.
18. Machado M, Cruz LS, Tannus and Fonseca M: Efficacy of clodronate, Pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a metaanalysis of randomized clinical trials. Clin Ther 31: 96-979, 2009.
19. Saad F: New research findings on zoledronic acid: survival, pain, and antitumour effects. Cancer Treat Rev 34: 18-192, 2008.
20. Sahi C, Knox JJ, Clemons M, Joshua AM and Broom R: Renal cell carcinoma bone metastases: clinical advances. Ther Adv Med Oncol 2: 7-83, 2010.
21. Zolnierek J, Nurzynski P, Langiewicz P, Oborska S, WaśkoGrabowska A, Kuszatal E, Obrocka B and Szczylik C: Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J Cancer Res Clin Oncol 136: 37-378, 2010.